Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
Study examines mental health prognosis of young VTE patients

Study examines mental health prognosis of young VTE patients

EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. The 2015 meeting is held 14 to 15 June in Dubrovnik, Croatia, in collaboration with the Croatian Association of Cardiology Nurses. [More]
Data from statewide quality collaborative helps surgeons to reduce rates of serious trauma complication

Data from statewide quality collaborative helps surgeons to reduce rates of serious trauma complication

As health insurers place more emphasis on paying for quality outcomes rather than for specific services provided by doctors and hospitals, several quality improvement programs have been developed as a way to help health care providers identify problem areas and share best practices. While some studies have evaluated how well these quality improvement programs achieve their goals, not many have focused on the area of trauma care. [More]
Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

A Creighton University researcher has received a National Institutes of Health grant to study the effects of gene and stem cell therapy in coronary artery bypass grafts, a first-of-its-kind undertaking that could transform the procedure, increase survival rates and dramatically reduce the possibility of re-occlusion of the grafted arteries and veins in the procedure. [More]
Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps that include the consistent use of experienced medical teams for a single type of surgery, preemptive antibiotics before the procedure, less reliance on potent opioids during recovery and urging patients to get out of bed and move around sooner can not only prevent infections, blood clots and other serious complications in people undergoing colorectal operations, but can also accelerate recovery and reduce cost of care, according to results of an ongoing program at The Johns Hopkins Hospital. [More]
Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Patients undergoing colon and rectal operations who participated in an innovative quality improvement (QI) program to speed their recovery and enhance results experienced shorter hospitalizations, reduced infection rates, and lower hospital costs, according to new study results. [More]
LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Blood clots often form when lipid-rich plaques on the inner surface of arteries rupture and platelets aggregate at the site of injury. Cardiologists from Ludwig-Maximilians-Universitaet in Munich have now compared the effects of two new platelet aggregation inhibitors. [More]
EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans. [More]
Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Researchers have created a new heart valve that combines a patient's own cells with metal alloy for a more durable replacement with potentially fewer complications, according to an article in the June 2015 issue of The Annals of Thoracic Surgery. [More]
Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
MD Anderson researchers find significant clinical variations among liver cancer patients

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need. [More]
Lung cancer surgery patients at higher risk of developing venous thromboembolism

Lung cancer surgery patients at higher risk of developing venous thromboembolism

New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery. [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE

Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE

Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Pradaxa's maker, Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for its blood thinner to treat DVT and PE. [More]
HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint. [More]
New Forsyth Institute study sheds light on connection between the mouth and heart

New Forsyth Institute study sheds light on connection between the mouth and heart

A new study from the Forsyth Institute is helping to shed more light on the important connection between the mouth and heart. According to research recently published online by the American Heart Association, scientists at Forsyth and Boston University have demonstrated that using an oral topical remedy to reduce inflammation associated with periodontitis, more commonly known as gum disease, also results in the prevention of vascular inflammation and can lower the risk of heart attack. [More]
New article highlights need for optimization of warfarin therapy

New article highlights need for optimization of warfarin therapy

Warfarin can be a challenging drug to manage. Long-term anticoagulation is recommended for patients with atrial fibrillation at risk of stroke, and for those with recurrent venous thrombosis or prosthetic heart valves. [More]
UM experts warn of serious risks associated with common IV devices

UM experts warn of serious risks associated with common IV devices

Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots. [More]
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). [More]
Advertisement
Advertisement